June 4, 2021
2020 Annual Report
Publication
As the HIV epidemic changes over time, and new pandemics continue to emerge, TAG continues to evolve while remaining true to our activist roots. We partner with the most affected communities in the U.S. and around the world.
June 3, 2021
TAG Urges Governor to Sign New York State Bill Expanding Adult Vaccines Available in Pharmacies
Statement / Press
The bill, S4807A (Stavisky) / A6476A (Hyndman), improves preventive viral hepatitis vaccine access, and is particularly important for people who use drugs and unhoused New Yorkers.
May 24, 2021
Community Engagement on TB through Storytelling
Publication
Storytelling is a tool that can help build understanding, support discussions between members of affected communities and other stakeholders, and aid in the identification of important issues and potential solutions. These storyboards follow three individuals journeys through diagnosis, treatment and care, and the barriers they face.
May 10, 2021
Time for $5 Coalition Statement: Cepheid’s Updated GeneXpert Pricing Does Not Address Country Needs
Statement / Press
The Time for $5 Coalition, comprised of over 150 civil society organizations globally, calls out Cepheid for the company’s insufficient and self-serving GeneXpert pricing packages for low- and middle-income countries (LMICs), announced May 6, 2021.
May 10, 2021
The TB Research Engine That Could: Sustaining the Success of TBTC Research in Turbulent Times
Publication
This publication explores the critical role the Tuberculosis Trials Consortium holds in increasing the store of knowledge about TB cures and other tools, demonstrates the implications that a lack of funding will have across the TB pipeline, and offers recommendations to ensure the gains made in TB research are not…
May 6, 2021
TAG Welcomes U.S. Government Support of Intellectual Property Flexibilities to Enable COVID-19 Vaccine Access
Statement / Press
Treatment Action Group (TAG) applauds the U.S. government’s decision to support the India-South Africa proposed waiver of certain intellectual property rights to enable equitable access to life-saving interventions for COVID-19.
May 6, 2021
Landmark TB Trials Results Published in New England Journal of Medicine
Statement / Press
Today the New England Journal of Medicine published results of a landmark phase III clinical trial that found a 4-month regimen containing rifapentine and moxifloxacin performed as well as the six-month standard regimen in curing drug-susceptible pulmonary TB.
April 4, 2021
TAG Comments on NIST’s Proposed Rulemaking Changes
Letter / Comment
TAG submitted comments in response to the National Institute of Standards and Technology’s (NIST) proposed change to rulemaking, strongly opposing amendments to remove crucial public health safeguards from the Bayh-Dole Act. March-in rights and other provisions to hold manufacturers accountable when federally funded inventions are exorbitantly priced and are critically…
April 1, 2021
Civil Society Letter to Donors, Countries, and Health Actors to Improve Access to GeneXpert and Other Diagnostics
Letter / Comment
TAG led an open letter appealing to donors, countries, and health actors to improve access to GeneXpert and other diagnostics for COVID-19, TB, HIV, HBV, HCV, and other diseases by applying collective leverage in negotiations with Cepheid for lower prices and sufficient volumes; establishing cost-of-goods-sold (COGS)-plus and volume-based pricing for…
March 25, 2021
Letters from TB Roundtable for Domestic and Global Appropriators, FY22
Letter / Comment
In March of 2021, the Tuberculosis Roundtable, of which TAG is a member organization, recently submitted letters to Congressional appropriators in support of increased funding for domestic and global TB programs for the 2022 fiscal year.